Jazz Pharmaceuticals Stock Earnings Reports

Jazz reported an exceptionally strong Q1 2026: total revenue of ~$1.07B (up >19% YoY) and non‑GAAP adjusted EPS of $6.34. Commercial momentum was broad-based — Xywav (sleep) grew 18% to $408M with ~16,600 active patients and ~425 net adds; Epidiolex (epilepsy) grew 15% to $250M with 16% volume growth and expansion focus in adults/long‑term care; oncology grew 45% driven by Zepzelca (Q1 sales $101M), Modeyso (Q1 sales $41M; ~500 patients treated since launch) and early traction for Ziihera (Zanidatamab) in biliary tract cancer (~$13M sales). Key pipeline and regulatory milestones: the sBLA for zanidatamab (Ziihera) in first‑line HER2+ metastatic GEA has priority review with a PDUFA date of August 25, 2026; HERIZON‑GEA showed a median OS of 26.4 months for the zanidatamab + tislelizumab + chemo triplet; multiple ongoing zanidatamab registrational trials (including breast cancer) and important interim OS readouts expected midyear and later in 2026/2027 (e.g., ACTION trial for Modeyso). Financial position is strong: Q1 operating cash flow ~$408M, cash & investments ~$2.9B, and management reaffirmed 2026 revenue guidance of $4.25–$4.5B while noting expected competitive dynamics in the oxybate market in H2 (generic high‑sodium oxybates and potential new wake‑promoting agents). Business development remains a priority (focus on rare disease; capacity to transact given cash position). Risks called out include competitive pressures, patent/litigation matters, and typical development/regulatory uncertainties.